BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Innovative Drug Delivery Systems, Inc. (IDDS) To Host Conference Call To Discuss Positive Pivotal Phase II/III Dyloject(TM) Results


10/19/2005 5:09:00 PM

NEW YORK--(BUSINESS WIRE)--July 25, 2005--Intrac, Inc. (OTC BB: ITRD.OB) and its wholly-owned subsidiary Innovative Drug Delivery Systems (IDDS) will host a conference call on Tuesday, July 26, 2005 beginning at 10:00 AM EDT to discuss the recently reported pivotal European Phase II/III study of Dyloject(TM) (diclofenac sodium injection). Results from the study demonstrated that Dyloject provided superior pain relief over 4 hours compared to placebo and therapeutic non-inferiority to Voltarol(R). These findings were the primary endpoints necessary to meet requirements for the Marketing Authorization Approval of Dyloject(TM). Additionally, preliminary analysis of the data did not reveal any unexpected safety signals and reported incidents of phlebitis in patients receiving Dyloject were half the rate of Voltarol. IDDS invites all those interested in hearing management's discussion of the Phase II/III study results to join the call by dialing (877) 407-9210 for domestic participants or (201) 689-8049 for international participants. Participants are asked to call the above numbers 5-10 minutes prior to the starting time.

Read at BioSpace.com


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->